What is the latest GRANULES stock price?
The latest stored price for GRANULES is Rs 858.15 as of 2026-08-21.
gimli
GRANULES stock AI analysis
GRANULES Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
GRANULES INDIA LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available GRANULES price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹858.15
1W return
-0.03%
1M return
-2.00%
3M return
+12.29%
6M return
+43.25%
1Y return
+85.75%
Market cap
₹21,264.69 cr
PE
32.10
PB
4.18
ROE
+15.05%
ROCE
+16.87%
RSI
53.79
Turnover
₹34.86 cr
Why it can matter in screens
- Momentum: GRANULES is above 50DMA, above 200DMA; RSI is 53.79.
- Returns: 1D +1.97%, 1W -0.03%, 1M -2.00%, 3M +12.29%, 1Y +85.75%.
- Trend levels: 52W high ₹910.00, 52W low ₹736.50, off high -5.70%.
- Liquidity: latest turnover is ₹34.86 cr; volume vs 20D is +0.66%.
- Valuation/profitability: PE 32.10, PB 4.18, ROE +15.05%, ROCE +16.87%.
- Growth: 3Y sales CAGR +5.89%, 3Y profit CAGR +4.82%.
Quick Answers
Is GRANULES above its 50DMA and 200DMA?
GRANULES is above 50DMA, above 200DMA. The latest 50DMA is 836.71 and the latest 200DMA is 675.12.
What are GRANULES PE, ROE and ROCE?
GRANULES has PE 32.10, ROE +15.05%, and ROCE +16.87% in Gimli's latest available snapshot.
How has GRANULES performed recently?
GRANULES has returned -2.00% over 1 month, +12.29% over 3 months, and +85.75% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 1,464.97 cr | 341.18 cr | 179.96 cr | 7.26 |
| 2026-03-31 | 1,457.43 cr | 376.79 cr | 201.57 cr | 8.23 |
| 2025-12-31 | 1,378.02 cr | 304.46 cr | 150.21 cr | 6.19 |
| 2025-09-30 | 1,294.67 cr | 277.08 cr | 130.61 cr | 5.38 |
| 2025-06-30 | 1,208.79 cr | 237.15 cr | 112.64 cr | 4.64 |
| 2025-03-31 | 1,196.82 cr | 285.03 cr | 152.03 cr | 6.27 |
| 2024-12-31 | 1,133.52 cr | 235.97 cr | n/a | 4.85 |
| 2024-09-30 | 956.52 cr | 206.57 cr | n/a | 4.01 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 5,338.92 cr | 1,195.48 cr | 595.02 cr | 24.47 |
| 2025-03-31 | 4,455.97 cr | 988.90 cr | 501.52 cr | 20.69 |
| 2024-03-31 | 4,490.16 cr | 826.32 cr | 405.31 cr | 16.73 |
| 2023-03-31 | 4,496.34 cr | 907.09 cr | 516.60 cr | 21.05 |
| 2022-03-31 | 3,255.95 cr | 728.47 cr | 386.52 cr | 15.55 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 7,719.95 cr | 880.24 cr | 1,512.04 cr | 5,084.99 cr |
| 2025-03-31 | 6,252.56 cr | 466.11 cr | 1,454.76 cr | 3,715.58 cr |
| 2024-03-31 | 5,520.98 cr | 381.10 cr | 1,315.06 cr | 3,225.54 cr |
| 2023-03-31 | 4,904.56 cr | 291.56 cr | 1,136.23 cr | 2,834.91 cr |
| 2022-03-31 | 4,512.90 cr | 184.71 cr | 1,106.31 cr | 2,587.09 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 793.25 cr | 235.04 cr | n/a |
| 2025-03-31 | 866.57 cr | 294.87 cr | n/a |
| 2024-03-31 | 439.41 cr | 58.84 cr | n/a |
| 2023-03-31 | 738.75 cr | 328.07 cr | n/a |
| 2022-03-31 | 332.06 cr | -65.65 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +38.02% | +17.50% | +16.11% | +3.45% | +28.38% | +0.00% |
| 2026-03-31 | +38.02% | +15.31% | +17.01% | +2.85% | +29.66% | +0.00% |
| 2026-02-23 | +38.02% | +13.79% | +18.51% | +4.28% | +29.69% | +0.00% |
| 2025-12-31 | +38.82% | +13.55% | +17.48% | +5.35% | +30.15% | +0.00% |
| 2025-09-30 | +38.82% | +14.09% | +17.92% | +6.54% | +29.17% | +0.00% |
| 2025-06-30 | +38.82% | +13.24% | +23.53% | +12.24% | +24.41% | +0.00% |
| 2025-03-31 | +38.84% | +15.15% | +22.45% | +11.57% | +23.57% | +0.00% |
| 2024-12-31 | +38.85% | +15.87% | +19.57% | +10.39% | +25.71% | +0.00% |
| 2024-09-30 | +38.87% | +19.49% | +14.87% | +7.86% | +26.78% | +0.00% |
| 2024-06-30 | +38.87% | +20.39% | +14.12% | +9.16% | +26.62% | +0.00% |
| 2024-03-31 | +41.96% | +19.57% | +10.70% | +7.09% | +27.76% | +4.03% |
| 2023-12-31 | +41.96% | +18.78% | +10.16% | +7.05% | +29.10% | +4.03% |
| 2023-09-30 | +41.96% | +21.48% | +7.06% | +3.94% | +29.50% | +4.03% |
| 2023-06-30 | +42.02% | +21.35% | +6.68% | +4.87% | +29.95% | +4.03% |
| 2023-03-31 | +42.02% | +23.90% | +5.03% | +3.76% | +29.05% | +4.03% |
| 2022-12-31 | +42.02% | +23.67% | +4.76% | +3.91% | +29.56% | +4.03% |
| 2022-10-19 | +42.02% | +22.65% | +4.23% | +3.38% | +31.10% | +10.84% |
| 2022-09-30 | +41.93% | +22.35% | +4.32% | +3.48% | +31.40% | +10.59% |
| 2022-06-30 | +41.98% | +0.00% | +26.16% | n/a | n/a | +10.59% |
| 2022-03-31 | +41.98% | +0.00% | +27.17% | n/a | n/a | +6.92% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze GRANULES INDIA with valuation, momentum and industry peers
- Compare GRANULES with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare GRANULES with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.